Objectives: To identify plasma biomarkers that can be early predictors of mortality in critically ill patients with primary influenza A/H1N1. Design: A prospective, multicenter, case-cohort pilot study. Setting: Three academic ICUs. Patients: Fifteen patients with primary influenza A/H1N1 that included seven survivors and eight nonsurvivors. For comparison, age-and gender-matched healthy controls (n = 27) were also studied. Interventions: Plasma was prepared from whole blood drawn on ICU admission in patients with influenza (ICU day 1). Microvesicle tissue factor activity, thrombin-antithrombin complexes, and D-dimers were measured as procoagulant markers and markers of activation of coagulation. Plasma cytokine levels were measured on the same blood samples in a subset of 12 patients with influenza using the Luminex Multi-Analyte Profiling system (Luminex Corporation, DeSoto, TX). Patients were followed up for the primary outcome of 28-day mortality. Measurements and Main Results: The average admission Acute Physiology and Chronic Health Evaluation II score of the patients was 25.5 ± 9.3, 60% of patients had shock, and the 28-day mortality rate was 53.3% (n = 8/15). Patients with influenza had dysregulated indices of coagulation and inflammation compared with controls. Among the markers of activation of coagulation measured on ICU day 1, only increased microvesicle tissue factor activity was significantly associated with subsequent influenzarelated mortality (5.6 ± 1.2 pg/mL in nonsurvivors vs 1.8 ± 0.8 pg/ mL in survivors; p < 0.05). Interleukin-8 was significantly higher in nonsurvivors compared with survivors (71.8 ± 29.1 pg/mL, n = 5 vs 17.3 ± 3.7 pg/mL, n = 7; p < 0.05). In addition, microvesicle tissue factor activity and interleukin-8 levels were significantly and positively correlated (r 2 = 0.60; p = 0.003). Other cytokines, thrombin-antithrombin complexes, and D-dimer were not different between nonsurvivors and survivors and did not correlate with illness severity or mortality. Conclusions: This study identifies an association between plasma interleukin-8 and microvesicle tissue factor activity measured on admission in patients with severe, primary influenza A/H1N1 infection and subsequent mortality. Thus, these biomarkers may serve as very early prognostic markers for patients with influenza A/H1N1. (Crit Care Med 2016; 44:e574-e578) 
I nfluenza A/H1N1 is a single-stranded RNA virus that causes a high number of ICU admissions, as well as considerable morbidity and mortality. Although effective treatments for influenza exist, treatment and triage decisions are still difficult because of a lack of accurate, reliable severity of illness predictive scores to determine the need for ICU admission (1) . Patients with influenza have alterations in hemostatic factors, thrombocytopenia, disseminated intravascular coagulation (DIC), and thrombosis (2) . We have shown that platelets are activated in critically ill patients with primary 2009 influenza A/H1N1 (3). In addition, influenza A/H1N1 infection causes a "cytokine storm." Given these prominent alterations in hemostasis and inflammation during influenza and their contribution to adverse outcomes, we sought to determine whether early indices of dysregulated coagulation and inflammation would be associated with influenza-related mortality.
Circulating microvesicles (also called "microparticles" or "extracellular vesicles") are small membrane fragments that can transfer messenger RNA and proteins between cells (4). Microvesicles are particularly prothrombotic when displaying tissue factor (TF) (4) . Viruses, such as influenza, induce TF expression in monocytes and endothelial cells and activate the coagulation cascade, which can result in DIC (5) . Influenza virus H1N1 also activates platelets and induces the release of microvesicles (6) . However, there are no studies reporting the levels of circulating TF-expressing microvesicles during the course of human influenza. In this study, we measured the levels of circulating microvesicle-TF activity and plasma cytokines in critically ill patients admitted with primary influenza A/H1N1 and tested their association with adverse clinical outcomes.
MATERIALS AND METHODS

Human Subject Enrollment
This was a prospective study of patients (n = 15) with primary influenza A/H1N1 who are 21 years old or older enrolled within 24 hours of ICU admission. For comparison, age-and gendermatched, healthy, medication free, nonhospitalized, consenting control subjects who are 21 years old or older were also studied (n = 27). The Institutional Review Boards approved this study (protocols: 28210 and 1005443), and all subjects or a legally authorized representative provided written informed consent. Influenza was diagnosed by reverse transcription-polymerase chain reaction on a respiratory sample (Roche Applied Science, Penzberg, Germany). Patients with concurrent, secondary bacterial infection at admission were excluded. The development of bacterial infections during patients' ICU course was evaluated by blood, sputum, and urine cultures and serologies. Demographics, laboratory data, and illness severity scores were captured on all patients. Overt DIC was calculated according to the International Society of Thrombosis and Hemostasis criteria, which has a high sensitivity and specificity for DIC but has some limitations, such as accounting for temporal changes. Patients were followed up prospectively for the primary outcome of all-cause, 28-day mortality.
Measurement of Microvesicle-TF Activity, Markers of Activation of Coagulation, and Cytokines
Plasma was prepared from acid-citrate dextrose-anticoagulated whole blood drawn at the time of study enrollment via centrifugation (1,500 rpm for 20 min). Plasma was immediately frozen at -80°C until microvesicle-TF, coagulation, and cytokine measurements. The levels of microvesicle-TF activity in plasma were measured by an in-house two-step FXa generation assay (7) . Briefly, microvesicles are pelleted by centrifugation of 200 μL of plasma and washed twice to remove the plasma. Microvesicles are resuspended in buffer and incubated with FVIIa (2.5 nM), FX (300 nM), and CaCl 2 (10 mM) for 2 hours at 37°C in the presence of either an inhibitory anti-TF antibody or a control antibody. Finally, levels of FXa are determined by adding a chromogenic substrate for 15 minutes at 37°C and measuring the absorbance at 405 nM with a VERSAmax microplate reader (Molecular Devices, LLC, Sunnyvale, CA). The level of microvesicle-TF activity in healthy controls is less than 0.05 pg/mL. Recombinant human TF (Innovin; Dade Berhing, Marburg, Germany) was used as a standard. Plasma levels of thrombinantithrombin complexes (TATc, normal < 4.0 ng/mL) and D-dimer (normal < 500 ng/mL) were quantified by enzymelinked immunosorbent assay using the TAT Enzygnost Micro Kit (Dade Behring/Siemens, Tarrytown, NY) and Asserachrom D-dimer kit (Diagnostica Stago, Parsippany, NJ), respectively. Plasma cytokine levels were measured using the Luminex MultiAnalyte Profiling system (LabMAP) technology (Luminex Corporation, DeSoto, TX).
Statistical Analyses
Data were examined for normality using skewness and kurtosis tests. Summary statistics were determined using STATA (version 11.0, StataCorp, College Station, TX). Groups were compared using the Student t test and the chi-squared test, as appropriate (GraphPad Software, version 5.0, GraphPad, La Jolla, CA; STATA version 11.0). Regression analyses were used to identify significant correlations between coagulation factors and mortality. A twotailed p value of less than 0.05 was considered significant.
RESULTS
On ICU admission, all patients with influenza A/H1N1 had acute respiratory distress requiring intubation and more than 50% of patients had shock requiring vasopressors ( Table 1) . Control subjects were well matched to a patient with influenza on the factors of age and gender and, as expected, had very low levels of microvesicle-TF activity (Table 1) . Patients with influenza had significantly higher plasma fibrinogen levels (571 ± 67 vs 308 ± 18 mg/dL; p < 0.001) and C-reactive protein (CRP) (11.0 ± 2 vs 2.2 ± 0.9; p < 0.001), consistent with a systemic inflammatory response and activation of the coagulation system during influenza.
However, although procoagulant markers and markers of activation of coagulation were all increased in patients with influenza compared with controls, only microvesicle-TF activity was associated with influenza-related mortality, being significantly higher in nonsurvivors compared with survivors (Table 1 ; Fig. 1A) . Platelet counts and fibrinogen levels were slightly lower in nonsurvivors but did not reach the significance (Table 1) . Microvesicle-TF activity, TATc levels, and D-dimer did not correlate with Acute Physiology and Chronic Health Evaluation II score, platelet count, fibrinogen levels, CRP, or age and did not significantly differ between male and female patients with influenza or between patients with severe sepsis versus septic shock (not shown).
Next, we examined plasma cytokine levels in patients with influenza and controls. Interleukin (IL)-2R, IL-8, and IL-10 were increased in patients with influenza A/H1N1 compared with control subjects, whereas IL-1β, IL-2, IL-4, IL-5, IL-12, IL-13, IL-17, and CD40L were not changed (Table 1) . We previously reported that IL-6 is also increased in patients with influenza A/H1N1 (3), consistent with the systemic inflammatory milieu during influenza. However, within the group of cytokines that increased in patients, only IL-8 was significantly associated with influenza-related mortality, being higher in nonsurvivors compared with survivors (Fig. 1B) . Interestingly, microvesicle-TF activity significantly correlated with IL-8 levels (Fig. 1C) .
DISCUSSION
In this study, we report that plasma microvesicle-TF activity and IL-8 levels are increased in patients with primary influenza A/H1N1 and are significantly associated with influenza-related mortality. Our study is consistent with a previous article that showed that four chemokines (IL-8, IP-10, monocyte chemoattractant protein-1, and monokine induced by interferon-γ) were associated with fatal outcome in patients infected with influenza A (H5N1) (8) . Other procoagulant markers and markers of inflammation or activation of coagulation were generally increased in patients with influenza but did not differ between survivors and nonsurvivors. Influenza virus can induce the expression of TF and the release of microvesicles, promoting a dysregulated procoagulant milieu (6) . We posit that microvesicle-TF activity in patients with influenza may not merely be a marker of severe infectious disease but may also contribute to adverse events, such as vascular thrombosis, organ failure, and death. Further studies are needed to extend these studies and to examine the biologic functions of microvesicle-TF during influenza infection. Our measurements of circulating microvesicle-TF activity and IL-8 levels were done within 24 hours of ICU admission and robustly identified patients who did not survive their infectious course. As such, microvesicle-TF activity and IL-8 may have utility as an early prognostic marker for patients with influenza A/H1N1. These findings build on and extend observations made in bacterial sepsis and acute allograft rejection, where TF+microvesicles correlate with adverse clinical outcomes (9) (10) (11) . In addition, because early plasma-based biomarkers for predicting influenza-related mortality remain largely absent, these results may be used to improve prognostication and risk-stratification efforts in the early stages of treatment for patients with severe influenza. In addition, our findings may help identify patients where more intensive monitoring or treatment may be warranted, for example, admission to an ICU setting.
The strengths of this study include its prospective multicenter design, robust determination of illness severity and complications, comprehensive characterization of markers of systemic activation of coagulation and inflammation, and inclusion of a matched healthy control cohort. The primary limitation of the study is the small sample size, and therefore, one must be cautious with interpretation of the data. Additional studies are needed to confirm our findings. However, critically ill patients with primary influenza A/H1N1 are challenging to prospectively identify and recruit. Thus, smaller studies of this nature are not uncommon within this field.
We also found that plasma IL-8 levels significantly correlated with microvesicle-TF activity in patients with influenza. Notably, there were no differences between influenza survivors and nonsurvivors with regard to demographics, illness severity, shock, DIC, or the need for and duration of mechanical ventilation. Thus, we do not believe that our findings that microvesicle-TF activity and IL-8 were associated with mortality are due, simply, to confounding bias. In addition, our findings highlight that traditional risk factors do not correlate with influenza-related mortality, as also described by others (2) .
Although the precise mechanism underlying our findings that microvesicle-TF activity and IL-8 were significantly correlated and predicted influenza mortality is unknown, we hypothesize that convergent signaling pathways through monocytes, macrophages, or other cells may contribute to the increased microvesicle-TF activity and IL-8 levels seen in our patients. Taken together, the findings of our study demonstrate, for the first time to our knowledge, that microvesicle-TF activity and IL-8 levels may have clinical utility as early biomarkers to identify patients with influenza at increased risk of mortality.
CONCLUSIONS
This study demonstrates that microvesicle-TF activity and IL-8 levels in patients with severe, primary influenza A/H1N1 infection are early markers associated with subsequent influenzarelated mortality.
